Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Multicenter, randomized, open-label, parallel group phase 2 study to assess the efficacy and
tolerance of four combinations of CBP501, cisplatin, and nivolumab administered once every 21
days to patients with stage IV exocrine pancreatic cancer and WBC < 10,000/mm3 at screening.